Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Marie de Charette
Observed names:
M. de Charette,
Marie De Charette
Institution:
Centre Hospitalier Universitaire de La Réunion
Observed institutions:
Centre National de la Recherche Scientifique,
Université de Lille,
Centre Hospitalier Universitaire de Lille,
Centre Hospitalier Universitaire de La Réunion,
Hôpital Claude Huriez,
Centre Hospitalier Universitaire de Rennes
show all 6
ORCID:
0000-0003-3108-0691
Observed ORCID:
0000-0003-3108-0691
OpenAlex ID:
A5028380185
Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?
2016
·
Marie de Charette
, Aurélien Marabelle
, et al.
·
European Journal of Cancer
·
161
Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy
2018
·
Marie de Charette
, Roch Houot
·
Haematologica
·
145
PDF
Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma
2020
·
G. Manson
, P. Brice
, et al.
·
European Journal of Nuclear Medicine and Molecular Imaging
·
13
Venetoclax–proteasome inhibitor–dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm
2024
·
Sabine Khalife-Hachem
, Arnaud Pages
, et al.
·
Blood Advances
·
7
PDF
Can palliative care consultation increase integration of palliative care for patients with hematologic malignancies?
2021
·
Chloé Prod’homme
, Licia Touzet
, et al.
·
Blood Advances
·
7
PDF
Successful and safe response to ibrutinib alone in treating relapsed Waldenström macrogobulinemia and related acquired von Willebrand syndrome: an option to consider
2022
·
Alexandre Butelet
, Stéphanie Poulain
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
3
An 80-Year-Old Woman With a Solitary Pulmonary Nodule
2020
·
Jean-Baptiste Gibier
, Magali Colombat
, et al.
·
CHEST Journal
·
2
PDF
Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial)
2025
·
N. Alshatti
, F. Lemonnier
, et al.
·
Immuno-Oncology Technology
·
1
PDF
Correction to: Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma
2021
·
G. Manson
, P. Brice
, et al.
·
European Journal of Nuclear Medicine and Molecular Imaging
PDF
Adult T-cell leukemia/lymphoma and Glucose-6-phosphate dehydrogenase deficiency rapidly diagnosed through blood smear examination
2020
·
Marie de Charette
, Coralie Derrieux
·
Blood Research
PDF
Show more works
View as search
Works count:
10
Citation count:
339
H-index:
5
I10-index:
3
Year
Topic
Type